Navigation Links
Blood vessel inhibitor shows promise against metastatic thyroid cancer
Date:7/2/2008

HOUSTON - Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by investigators from The University of Texas M. D. Anderson Cancer Center reports in the July 3rd edition of The New England Journal of Medicine.

The investigational drug, motesanib diphosphate, is a VEGF inhibitor, a biologic agent that targets receptors on a protein known as vascular endothelial growth factor (VEGF). VEGF is instrumental in angiogenesis (formation of new blood vessels), a process that allows tumors to grow and spread.

Study lead author Steven I. Sherman, M.D., chair and professor of M. D. Anderson's Department of Endocrine Neoplasia and Hormonal Disorders, noted strong evidence that VEGF receptors play an important role in metastatic thyroid cancer, a disease with few treatment options.

"There is no standard accepted chemotherapy for advanced metastatic differentiated thyroid cancer, and response rates have typically been 25 percent or less," Sherman said. "Most patients are not treated with systemic chemotherapy because the limited benefit rarely justifies the side effects. Treatment of thyroid cancer has been a completely unmet need."

Sherman, colleagues in 10 countries, and scientists from Amgen, which is developing motesanib diphosphate (AMG 706), planned and conducted one of the largest clinical trials ever done for metastatic thyroid cancer.

Of the 93 patients with rapidly progressing cancer who were enrolled in the study, 49 percent had a positive response. From that group 14 percent had their tumors shrink and 35 percent had their tumors stabilize for more than 24 weeks. Median progression-free survival was estimated to be 40 weeks.

Genetic analyses of 25 patients indicated that those with a specific mutation known as BRAF V600E in their tumors had a better
'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Page: 1 2 3 4

Related medicine news :

1. Specific antagonism lowers blood pressure
2. Restricting Blood Flow May Help Heart Bypass Patients
3. FDA Updates Prescription Guidelines for Blood Thinner
4. Doctors Often Miss High Blood Pressure in Kids
5. Back to School Means Return of School Blood Drives
6. Blood-flow detector software show promise in preventing brain damage
7. FDA Approves New Roche West Nile Virus Blood Screening Test
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Laser blasts viruses in blood
10. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
11. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood vessel inhibitor shows promise against metastatic thyroid cancer
(Date:12/25/2014)... 2014 This is a professional and ... Sterilizers industry with a focus on the Chinese market. ... of the Sterilizers manufacturers and is a valuable source ... in the industry. This report provides a basic overview ... technology. In this part, the report presents the company ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... the popular online supplier of wedding dresses and special occasion ... black one-shoulder cocktail dresses . In addition, all these elegant ... prices, up to 70% off. , The development ... You know, we have thousands of frequent callers in the ... can visit our website for more details. The current special ...
(Date:12/25/2014)... Angeles, CA (PRWEB) December 25, 2014 The ... Dolcemaschio was created in honor of a true 9/11 ... at two film festivals including the 24 hours of Nuremberg ... Festival in Bangladesh. , Actress, screenwriter and director ... helped produce this film together with her husband, Gregory ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... , , BRONX, N.Y., Aug. 3 ... raising their risk of bone and heart disease, according to a study ... striking findings suggest that vitamin D deficiency could place millions of children ... disease. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090803/DC55348 ...
... But another study finding suggests insulin treatment could boost ... Metformin, one of the most widely used diabetes drugs, ... odds for pancreatic cancer by 60 percent, a new ... Other common treatments, including the use of insulin or ...
... ER treatments since 1990 , SUNDAY, Aug. 2 (HealthDay News) ... climbing for fun and exercise, the number of injuries related ... study on the subject. , More than 40,000 people sought ... fractures, sprains and other ailments related to rock-climbing -- a ...
... ... be joining dental sleep medicine,s top sleep and dental sleep professionals at Somnomed,s first annual ... ... Isn,t Sexy, LLC will be joining dental sleep medicine,s top sleep and dental sleep professionals ...
... cell lung cancer (NSCLC) patients over the age of ... erlotinib, Fox Chase Cancer Center researchers reported today at ... Study of Lung Cancer. "Based on our initial ... efficacious, though we,ll have to wait and see the ...
... , NASHVILLE, Tenn., Aug. 1 HCA Healthcare announces the following Webcast: , , ... Healthcare Webcast , , When: August ... http://www.videonewswire.com/event.asp?id=60459 , , How: ... the web at the address above. , , Contact: ...
Cached Medicine News:Health News:Millions Of U.S. Children Low In Vitamin D 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 2Health News:Metformin May Lower Diabetics' Odds for Pancreatic Cancer 3Health News:Rock-Climbing Injury Rate Soaring 2Health News:Laurence I. Barsh, DMD, Founder of Snoring Isn't Sexy, to speak at Somnomed's First Annual Symposium 2Health News:Fox Chase finds all-biologic regimen efficacious and well-tolerated in elderly lung cancer patients 2
(Date:12/24/2014)... OTTAWA , Dec. 24, 2014 /CNW/ - ... Superburn" is being recalled after Health Canada tests confirmed ... serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire ... is recalling the product from retail stores across ... body building purposes, including for weight loss and increased ...
(Date:12/24/2014)...  Commonwealth Cornerstone Group (CCG) today announced the completion of ... to help fund the expansion and consolidation of healthcare services ... . PHN is the largest federally ... It is the largest employer in Sharon,s ... staff. Currently, PHN Sharon offers scattered services out ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... BETHLEHEM, Pa., March 21, 2012  Particle Sciences, Inc., a ... with Pernix Therapeutics, a specialty pharmaceutical company, a new ... Mark Mitchnick, CEO of Particle Sciences, said, "There ... unmet need is in the delivery of these agents ...
... first time in state of New York, PediaVision will provide ... approximately 125 of the children at Boys & Girls Club ... York, on Thursday, March 22 beginning at 3 p.m.  ... from the Spot screening are provided with the necessary follow-up ...
Cached Medicine Technology:PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 2PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 3PediaVision to Conduct Free Screenings With "Spot" at Kips Bay Boys & Girls Club 4
PG Magnum Cup Curettes with large capacity cup sizes, total length 12.6" (32 cm) handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm)....
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Bone Curette, 170 mm...
Bone Curette, 145 mm...
Medicine Products: